3 U.S. lawmakers have disclosed 5 Genmab A/S trades under the STOCK Act — 5 buys and 0 sells between 2018 and 2026. Congress has been net buyers of GMAB, and their disclosed buys are up 21.3% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of GMAB, marked to the latest close — per-share (share counts aren't disclosed).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2026-03-30 | Alan Armstrong | BUY | $1K–$15K | $25.83 | $31.34 2026-08-13 | +21.3% |
| 2020-11-20 | Thomas R Carper | BUY | $1K–$15K | $36.53 | $31.34 2026-08-13 | -14.2% |
| 2020-11-20 | Thomas R Carper | BUY | $1K–$15K | $36.53 | $31.34 2026-08-13 | -14.2% |
| 2018-12-12 | James B. Renacci | BUY | $15K–$50K | $15.99 | $31.34 2026-08-13 | +95.9% |
| 2018-02-28 | James B. Renacci | BUY | $1K–$15K | $20.80 | $31.34 2026-08-13 | +50.7% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
3 members of the U.S. House and Senate have disclosed Genmab A/S transactions under the STOCK Act — 5 purchases and 0 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
No member of Congress has disclosed a GMAB purchase in the last 90 days. STOCK Act filings lag the trade by up to 45 days, so newer buys may still be pending disclosure.
Notional-weighted, lawmakers' disclosed GMAB buys are up 21.3% versus the latest close of $31.34. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded GMAB and how it performed.